AKBA
Akebia Ther
NASDAQ: AKBA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.36
-4.23% today
Updated 2026-04-29
Market cap
$364.82M
P/E ratio
—
P/S ratio
1.55x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$1 – $4
Volume
2.7M
Akebia Ther (AKBA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$1.36
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.2B | $0.3B | $0.2B | $0.2B | $0.2B | $0.2B | $0.2B | $0.2B | $0.2B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: -4.37% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -2.26%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.